ALZN
Alzamend Neuro Inc
NASDAQ: ALZN · HEALTHCARE · BIOTECHNOLOGY
$1.14
+7.55% today
Updated 2026-04-30
Market cap
$4.22M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.67
Dividend yield
—
52W range
$1 – $6
Volume
0.1M
Alzamend Neuro Inc (ALZN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | $23066.00 | $50740.00 | $50740.00 |
| Gross profit | — | — | — | — | — | — | — | $-23066.00 | $-50740.00 | $-50740.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| R&D | — | $275047.00 | $323403.00 | $3.70M | $1.07M | $1.31M | $5.20M | $7.45M | $6.46M | $1.41M |
| SG&A | $69456.00 | $942511.00 | $545118.00 | $1.31M | $3.35M | $3.64M | $7.12M | $6.68M | $3.48M | $3.08M |
| Operating income | $-69456.00 | $-1.55M | $-898000.00 | $-5.01M | $-4.42M | $-4.95M | $-12.32M | $-14.87M | $-9.94M | $-4.50M |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| EBITDA | — | $-21501.00 | $7341.00 | $-5.01M | $-4.42M | $-4.95M | $-12.32M | $-14.85M | $-9.89M | $-4.45M |
| EBITDA margin | — | — | — | — | — | — | — | — | — | — |
| EBIT | $-69456.00 | $-1.57M | $-891089.00 | $-5.01M | $-4.42M | $-9.90M | $-12.32M | $-14.87M | $-9.94M | $-4.50M |
| Interest expense | — | $0.00 | $0.00 | $0.00 | $13925.00 | $158803.00 | $46524.00 | $7701.00 | $10101.00 | $18029.00 |
| Income tax | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-69456.00 | $-1.57M | $-932000.00 | $-4.86M | $-4.40M | $-5.05M | $-12.36M | $-14.88M | $-9.95M | $-4.51M |
| Net income growth (YoY) | — | -2160.4% | +40.6% | -421.7% | +9.6% | -14.8% | -144.9% | -20.4% | +33.1% | +54.6% |
| Profit margin | — | — | — | — | — | — | — | — | — | — |